Carmignac Gestion Biomarin Pharmaceutical Inc Transaction History

Carmignac Gestion

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$85.07 - $94.48 $92 Million - $102 Million	-1,081,856 Reduced 99.99%	100 $8,000
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $3.26 Million - $3.77 Million	37,585 Added 3.6%	1,081,956 $93.8 Million
Q1 2023 May 12, 2023	BUY	$87.74 - $117.27 $15.4 Million - $20.6 Million	175,759 Added 20.23%	1,044,371 $102 Million
Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $70.3 Million - $94.4 Million	868,612 New	868,612 $89.9 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Carmignac Gestion, based on Form 13F filings with the SEC.

Stay updated on Carmignac Gestion with notifications on news.